XORTX Therapeutics (XRTX) Registration Filing summary

Company overview and business model

• Focuses on developing therapies for diseases modulated by aberrant purine and uric acid metabolism, targeting gout, autosomal dominant polycystic kidney disease (ADPKD), type 2 diabetic nephropathy (T2DN), and acute kidney injury (AKI) associated with respiratory virus infection.

• Pipeline includes four programs: XRx-026 (gout), XRx-008 (ADPKD), XRx-101 (AKI), and XRx-225 (T2DN), with XRx-026 prioritized for near-term marketing approval.

• Proprietary platforms leverage novel formulations of oxypurinol and xanthine oxidase inhibitors, aiming for modular, scalable, and customizable therapies.

• Holds exclusive patents in the US and Europe for uric acid lowering agents and proprietary formulations.

Financial performance and metrics

• As of June 30, 2025, pro forma as adjusted cash was $5.9 million, with total equity of $7.1 million and total capitalization of $7.9 million.

• Net tangible book value per share post-offering is estimated at $0.69, with immediate dilution to new investors of $0.11 per share.

• Incurred operating losses and negative cash flow for fiscal years ended December 31, 2024 and 2023.

Use of proceeds and capital allocation

• Net proceeds of approximately $3.8 million expected, primarily allocated to ongoing R&D, working capital, and general corporate purposes.

• Management retains broad discretion over allocation of funds.